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A B S T R A C T   
Objectives: To determine the extent and characteristics of delay in breast cancer diagnosis in women recalled at 
screening mammography. 
Methods: We included a consecutive series of 817,656 screens of women who received biennial screening 
mammography in a Dutch breast cancer screening region between 1997 and 2016. During at least 3.5 years 
follow-up, radiological reports and biopsy reports were collected of all recalled women. The inclusion period was 
divided into four cohorts of four years each. We determined the number of screen-detected cancers and their 
characteristics, and assessed the proportion of recalled women who experienced a diagnostic delay of at least 4 
months in breast cancer confirmation. 
Results: The proportion of recalled women who experienced diagnostic delay decreased from 7.5 % in 
1997− 2001 (47/623) to 3.0 % in 2012− 2016 (67/2223, P < 0.001). The proportion of women with a delay of at 
least two years increased from 27.7 % (13/47) in 1997− 2001 to 75.7 % (53/70) in 2012− 2016 (P < 0.001). 
Cancers with a diagnostic delay > 2 years were more frequently invasive (P = 0.009) than cancers with a 
diagnostic delay of 4− 24 months. The most frequent cause of diagnostic delays was incorrect radiological 
classifications by clinical radiologists (55.2 % overall) after recall. 
Conclusions: The proportion of recalled women with a delayed breast cancer diagnosis has more than halved 
during two decades of screening mammography. Delays in breast cancer diagnosis are characterized by longer 
delay intervals, although the proportion of these delays among all screen-detected cancers has not increased. 
Preventing longer delays in breast cancer confirmation may help improve breast cancer survival.   
1. Introduction 
In many countries breast cancer is one of the most commonly diag-
nosed malignancies in women [1]. Screening mammography pro-
grammes have been established with the aim to reduce breast cancer 
morbidity and mortality through early detection and treatment of the 
disease. In combination with improved therapy, this early detection has 
resulted in a significant reduction of breast cancer mortality over the 
past decades [2,3]. After recall for a suspicious abnormality at screening 
mammography, a timely confirmation of a breast malignancy is of 
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utmost importance in order to prevent a treatment delay. A diagnostic 
delay after recall may cause the tumour to be diagnosed in a more 
advanced stage, which could have a negative impact on breast cancer 
survival [4]. 
Several studies have shown that up to 5% of recalled women expe-
rience a delay in the confirmation of their breast cancer. [5,6] Most of 
these studies have been performed in the era of screen-film mammog-
raphy (SFM). Currently, full-field digital mammography (FFDM) has 
replaced screen-film mammography in both the screening setting and in 
the setting of clinical mammography in most countries. Also, the man-
agement of breast disease has changed considerably over the years, with 
the introduction of new diagnostic modalities (digital breast tomosyn-
thesis, 3D ultrasonography, spectral mammography, advanced magnetic 
resonance techniques), replacement of fine needle aspiration cytology 
by core biopsy, implementation of multidisciplinary meetings, and a 
further specialization of health care professionals in breast diseases [6]. 
For these reasons, one may assume that the proportion of women who 
face a delay in their breast cancer diagnosis after recall at screening 
mammography has decreased over time. At the same time, a reduction in 
length of delay is expected due to increased diagnostic accuracy pre-
venting false positive recall and repeated recall, while also reducing the 
need for radiological follow-up in cases of equivocal findings at 
mammography or ultrasound. We therefore determined trends in the 
frequency of delayed breast cancer confirmation and lengths of delays in 
women recalled at screening mammography. We also assessed the 
causes of these delays and investigated tumour characteristics of these 
breast cancers with short and longer delay intervals in an observational 
follow-up study spanning two decades of screening mammography 
conducted in the south of the Netherlands. 
2. Material and methods 
2.1. Study population and screening procedure 
We included a consecutive series of 817,656 screens (SFM: 49,318 
initial screens and 328,637 subsequent screens; FFDM: 48,223 initial 
screens and 391,478 subsequent screens) of women aged 50–75 years 
who received biennial screening mammography in a southern region of 
the Netherlands between January 1, 1997 and December 31, 2016 
(Table 1). Women participating in the screening programme can indi-
cate that they do not give permission to use their data for quality 
assessment and scientific purposes. Three recalled women did not give 
this permission and they were excluded from analysis. Ethical approval 
was waived by the Dutch Central Committee on Research involving 
Human Subjects (CCMO). 
All screening mammograms were obtained by certified radiogra-
phers at one of four dedicated screening units (one fixed unit and three 
mobile units). Screen-film mammography was replaced by full-field 
digital mammography in 2009/2010. The examinations were 
routinely and independently double read by a team of 17 certified 
screening radiologists. The examinations were routinely and indepen-
dently double read by a team of 17 certified screening radiologists, each 
reading more than 10,000 screening mammograms yearly. The radiol-
ogists classified the mammographic abnormality in case of recall 
(suspicious mass, suspicious calcifications, suspicious mass in combi-
nation with calcifications, asymmetry, architectural distortion or other 
suspicious abnormality). Recalled women were referred by their general 
practitioner to a hospital breast unit for further analysis of the 
mammographic abnormality. In case of a false positive recall (i.e., no 
breast cancer at workup) women were encouraged to return to the 
screening programme. 
2.2. Workup of recalled women and follow-up 
A total of 36 hospitals were involved in the workup of recalled 
women, of which the majority (99.4 %, 18,476/18,592) was analysed in 
eight hospitals centrally located in our screening region. Recalled 
women first underwent physical examination by a surgical oncologist or 
dedicated breast nurse at the surgical department. The type of diagnostic 
workup was at the discretion of the clinical radiologist and could include 
additional mammographic views, breast tomosynthesis, breast ultraso-
nography (including 3D ultrasonography) and/or magnetic resonance 
imaging of the breasts. Clinical breast imaging was followed by percu-
taneous breast biopsy if indicated, and included fine needle aspiration 
biopsy (FNAB), ultrasound guided core needle biopsy (CNB, 14–18 
Gauge) and/or vacuum assisted core needle biopsy (9–11 Gauge, either 
stereotactic guided or MRI guided). The use of surgical biopsy for 
diagnostic purposes sharply declined over the years and is currently 
reserved for those cases where malignancy has not been ruled out by 
percutaneous biopsy. [7] Recalled women were discussed at multidis-
ciplinary meetings that were gradually implemented in the hospitals. 
During a minimum of 3.5 years follow-up (until July 1, 2020), one of 
the screening radiologists (LD) and several radiology residents collected 
clinical data and data from diagnostic breast imaging, biopsy procedures 
and surgical interventions of all recalled women. The radiologist entered 
these data in a database which had been constructed for quality assur-
ance of the regional screening programme. Breast cancers were cate-
gorized into ductal carcinoma in-situ (DCIS) and invasive cancers. 
Lobular carcinoma in-situ was considered a non-malignant lesion. The 
TNM classification (6th and 7th edition) was used for malignant lesions. 
[8,9] For women with a bilateral malignancy, the cancer with the 
highest TNM was retained and multiple foci of cancer in one breast were 
counted as one cancer. 
2.3. Delayed breast cancer diagnosis 
In the current study, we defined an interval of at least four months 
between the recall at screening mammography and the confirmation of 
breast cancer as a diagnostic delay. The 20-year inclusion period was 
divided into four cohorts of five years each: 1997− 2001, 2002− 2006, 
2007− 2011 and 2012− 2016. For each cohort, we determined the 
number of and characteristics of detected cancers at recall, and assessed 
the proportion of recalled women who experienced a diagnostic delay of 
at least 4 months in breast cancer confirmation. The database for quality 
assurance was used to determine the interval between recall and time of 
diagnosis of breast cancer to determine whether an interval of at least 
four months between recall and diagnosis had occurred. The database 
for quality assurance was also used to identify women who had been 
Table 1 
Proportions of women with a diagnostic delay in breast cancer diagnosis after recall at screening mammography.   
Year of screening Total  
1997− 2001 2002− 2006 2007− 2011 2012− 2016  
Screens, N 128081 155398 209523 324654 817616 
Recalls, N 1324 2123 4972 10173 18592 
Screen detected cancers, N 568 750 1227 2148 4693 
Cancers with a diagnostic delay, N (%) 47 (7.6) 53 (6.6) 69 (5.3) 70 (3.1) 239 
Delay 4− 24 months 34 (72.3) 34 (64.2) 21 (30.4) 17 (24.3) 106 (44.4) 
Delay >24 months 13 (27.7) 19 (35.8) 48 (69.6) 53 (75.7) 133 (55.6)  
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recalled twice for the same mammographic abnormality between 
January 1997 and January 2017. A team of three radiologists (WS, FJ, 
LD) then determined whether the second recall concerned the same 
mammographic abnormality for which a woman had been recalled 
previously. Each case was independently assessed by two radiologists 
and discrepant observations between them were solved by consensus. To 
determine whether an incorrect radiological assessment after recall had 
resulted in a diagnostic delay, the radiologists also independently and 
retrospectively reviewed the screening mammograms and diagnostic 
breast imaging and intervention reports of all women with a diagnostic 
delay. Each reviewer classified the lesions using the Breast Imaging 
Reporting and Data System (BI-RADS). [10,11] Finally, the radiologists 
reviewed the clinical data (including biopsy reports, discharge records, 
outcome of multi-disciplinary team meetings) to identify other causes 
than a false negative radiological assessment for a delayed breast cancer 
diagnosis, including false-negative biopsy results or patient related 
delays. 
Parameters such as tumour histology, nodal involvement, histologi-
cal grading and surgery performed were calculated for women with a 
delay of respectively 4− 24 months or a delay of at least 24 months 
between recall and breast cancer diagnosis. We also compared these 
characteristics of breast cancers with a diagnostic delay with those of 
screen-detected cancers without this delay. 
2.4. Statistical analysis 
Descriptive statistics were performed using Statistical Package for 
Social Science 23.0 (SPSS Inc., IBM, Chicago, IL). The chi-square test was 
used to test for differences between women with a diagnostic delay of 
4− 24 months and women with a diagnostic delay of at least 24 months 
with respect to tumour characteristics i.e. histology, stage, nodal status, 
receptor status, and type of final surgical treatment. The proportions of 
women with diagnostic delays (4− 24 months versus >24 months) in the 
four time periods (1997− 2001, 2002− 2006, 2007− 2011, and 
2012− 2016) were tested using the chi-square test. Each delay was 
categorized according to causes of delayed diagnosis over the time pe-
riods as mentioned above, and differences in proportions were tested 
using the chi-square test. Her2/Neu-receptor status was routinely 
determined from 2008 onward and thus not available for the earlier 
inclusion periods. Missing data were excluded in the Chi-square test 
analyses when comparing tumour characteristics for the two delay co-
horts. A P-value of less than 0.05 was considered to indicate a statisti-
cally significant difference. P-values were two-sided. 
3. Results 
3.1. Overall screening outcome 
A total of 18,592 women were recalled at screening mammography 
(recall rate: 2.3 % (18,592/817,656)), of whom 4693 proved to have 
breast cancer at workup (6.0 cancers detected per 1000 screens (4693/ 
817,656), positive predictive value of recall: 25.2 % (4693/18,592). The 
4693 screen detected cancers comprised 907 DCIS (19.3 %) and 3786 
(80.7 %) invasive cancers. 
3.2. Women with a delayed diagnosis of breast cancer 
A delay in breast cancer diagnosis of at least four months was present 
in 4.8 % of recalled women with breast cancer at workup (239/4932). 
This percentage gradually decreased from 7.6 % in 1997− 2001 (47/ 
615) to 3.1 % in 2012− 2016 (70/2218, P < 0.001, Table 1). 
Among all delays, the proportion of women with a delay of at least 24 
months increased from 27.7 % (13/47) in 1997− 2001 to 75.7 % (53/70) 
in 2012− 2016 (P < 0.001). Fig. 1 shows the number of delayed cancer 
diagnosis per 1000 screen-detected cancers. A decline in the rate of 
cancers with a 4− 24 months diagnostic delay is seen over the years, 
whereas the rate of cancers confirmed at least 24 months after recall 
remained stable (except for the cohort screened 2007− 2011). 
In 93.2 % (124/133) of the women with a delay of at least 24 months, 
the breast cancer was finally confirmed after a second recall for the same 
lesion for which she had been recalled previously. This second recall 
took place at the subsequent screen, two years after the initial recall, in 
59.7 % of the women (74/124) and at a later subsequent screening 
round in 40.3 % (50/124). Six women, who preferred opportunistic 
screening rather than returning to the screening programme, proved to 
have breast cancer at one of the subsequent opportunistic screening 
mammograms. Two women with a palpable breast lump consulted a 
surgical oncologist more than two years after their false positive recall, 
with breast cancer confirmed at the site of the previous abnormality at 
screening mammography. One diagnostic delay was due to a patient’s 
refusal to undergo biopsy. Cancers with a diagnostic delay of at least 2 
years were more frequently invasive (P = 0.009), but showed a similar 
Bloom & Richardson grading (P = 0.16) compared to cancers with a 
diagnostic delay of 4− 24 months (Table 2). Tumour size and lymph 
node status were comparable for both groups, as well as the type of 
surgical treatment (breast conserving surgery versus mastectomy). 
Tumour characteristics of breast cancers with a delayed diagnosis 
were also compared to those of screen-detected cancers without a 
diagnostic delay, as shown in Table 3. The two groups differed in his-
tological profile, with more ductal and ductolobular cancer among 
screen-detected breast cancers (P < 0.001). Screen-detected, invasive 
Fig. 1. Time trend in number of delays per 1000 screen detected cancers.  
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cancers were more frequently lymph node positive (23.8 % (905/3786 
versus 19.1 % (38/239), although this difference was not statistically 
significant (P = 0.24). The Bloom and Richardson tumour grading was 
comparable for both groups (P = 0.58). Patients with a diagnostic delay 
were more likely to be treated with mastectomy (21.8 % versus 14.3 %, 
P < 0.001). 
3.3. Causes of diagnostic delays 
In all 4 cohorts an incorrect radiological classification given by the 
clinical radiologists after recall was the most frequently encountered 
cause of a diagnostic delay (Table 4). These women received a BI-RADS 
1 (no abnormalities) or BI-RADS 2 (benign) classification at workup, 
without additional biopsy. The reviewing study radiologists (LD, WS, 
FJ), however, considered the lesions suspicious or malignant in retro-
spect, with the necessity of subsequent biopsy. Examples of erroneous 
BI-RADS classifications are shown in Figs. 2 and 3. 
Among all delays, the proportion of women with an erroneous 
radiological classification increased from 42.6 % in 1997/2001 (20/47) 
to 72.9 % in 2012− 2016 (51/70, P = 0.001) and this increase was most 
prominent in women with diagnostic delays of at least 24 months 
(Fig. 4). False negative percutaneous biopsy was another major cause of 
a diagnostic delay and comprised 15.7 % (2012− 2016) to 30.2 % 
(2002− 2006) of all delays in the screened cohorts. The proportion of 
women who experienced a delayed breast cancer confirmation as a 
result of radiological surveillance of a probably benign lesion at radi-
ology significantly decreased over the years, from 21.3 % (10/47) in 
1997− 2001 to 5.7 % (4/70) in 2012− 2016 (P = 0.01). None of the 
Table 2 
Tumour characteristics and surgical therapy of breast cancers with a diagnostic 
delay of 4-24 months versus a diagnostic delay of at least 2 years.   
Delay in breast cancer 
diagnosis 4− 24 
months (N = 106) 
Delay in breast 
cancer diagnosis >2 
years (N = 133) 
P 
Type of cancer, N (%)   0.007 
DCIS 26 (24.5) 15 (11.5)  
Invasive 80 (75.5) 118 (88.5) 
Histology of invasive 
cancers, N (%)   0.92 
Ductal 58 (72.5) 88 (74.6)  
Lobular 11 (13.8) 14 (11.8)  
Ductolobular 1 (1.3) 1 (0.8)  
Other 8 (10.0) 15 (12.8)  
Unknown 2 (2.5) 0  
Tumour stage of 
invasive cancers, N 
(%)   
0.40 
T1a + b 33 (41.3) 39 (33.1)  
T1c 33 (41.3) 56 (47.5) 
T2+ 12 (15.0) 23 (19.4)  
Unknown 2 (2.5) 0  
Lymph node status of 
invasive cancers, N 
(%)   
0.08 
N+ 20 (25.0) 18 (15.3)  
N- 57 (71.3) 97 (82.2) 
Unknown 3 (3.8) 3 (2.5) 
Bloom & Richardson 
grade, N (%)   
0.16 
I 31 (38.8) 45 (38.1)  
II 22 (27.6) 56 (47.5)  
III 12 (15.0) 15 (12.8)  
Unknown 15 (18.8) 2 (1.6)  
Estrogen receptor 
status, No (%)   
0.90 
Positive 66 (82.5) 105 (88.9)  
Negative 8 (10.0) 12 (10.3)  
Unknown 6 (7.5) 1 (0.8)  
Progesterone receptor 
status, No (%)   0.08 
Positive 58 (72.5) 77 (65.3)  
Negative 16 (20.0) 39 (33.1)  
Unknown 6 (7.5) 2 (1.6)  
Her2/Neu receptor 
status, No (%)   
0.020* 
Positive 9 (11.3) 9 (7.6)  
Negative 31 (38.8) 98 (83.1)  
Unknown 40 (50.0) 11 (9.3)  
Final surgical 




74 (69.8) 106 (79.7)  
Mastectomy 27 (25.5) 25 (18.6) 
No surgery 5 (4.7) 2 (1.5) 
DCIS =Ductal carcinoma in-situ *In earlier cohorts (until 2008), Her2/Neu re-
ceptor status was not routinely reported, yielding a large number of missing 
data. Missing numbers were not incorporated in the Chi-square test. 
Table 3 
Tumour characteristics and surgical therapy of breast cancers with a diagnostic 
delay versus screen detected cancers without delay.   
Breast cancers with 
diagnostic delay 
(N = 239) 
Screen detected 
cancers (no delay) 
(N = 4693) 
P 
Type of cancer, N (%)   0.41 
DCIS 41 (17.2) 907 (19.3)  
Invasive 198 (82.8) 3786 (80.7) 
Histology of invasive 
cancers, N (%)   <0.001 
Ductal 146 (73.7) 2943 (77.7)  
Lobular 25 (12.6) 453 (11.9) 
Ductolobular 2 (1.0) 159 (4.2) 
Other 23 (11.6) 214 (5.6) 
Unknown 2 (1.1) 17 (0.5) 
Tumour stage of 
invasive cancers, N 
(%)   
0.47 
T1a + b 72 (36.3) 1246 (32.9)  
T1c 89 (44.9) 1735 (45.8) 
T2+ 35 (17.6) 786 (20.7) 
Unknown 2 (1.2) 19 (0.6) 
Lymph node status of 
invasive cancers, N 
(%)   
0.24 
N+ 38 (19.1) 905 (23.9)  
N- 154 (77.7) 2801 (73.4) 
Unknown 6 (3.2) 80 (2.7) 
Bloom & Richardson 
grade, N (%)   
0.58 
I 76 (38.3) 1563 (41.3)  
II 78 (39.4) 1520 (40.1) 
III 27 (13.6) 453 (14.0) 
Unknown 17 (8.7) 250 (4.6) 
Estrogen receptor 
status, No (%)   
0.99 
Positive 171 (86.4) 3279 (86.6)  
Negative 20 (10.1) 376 (9.9) 
Unknown 7 (3.5) 131 (3.5) 
Progesterone receptor 
status, No (%)   0.74 
Positive 135 (68.2) 2678 (70.7)  
Negative 55 (27.7) 968 (25.6)  
Unknown 8 (4.1) 140 (3.7) 
Her2/Neu receptor 
status, No (%)   
0.38* 
Positive 18 (9.1) 278 (7.3)  
Negative 129 (65.2) 2635 (69.6) 
Unknown 51 (25.7) 873 (23.1) 
Final surgical 




180 (75.3) 3966 (84.5)  
Mastectomy 52 (21.8) 673 (14.3)  
No surgery 7 (2.9) 54 (1.2) 
DCIS = Ductal carcinoma in-situ *In earlier cohorts (until 2008), Her2/Neu re-
ceptor status was not routinely reported, yielding a large number of missing 
data. Missing numbers were not incorporated in the Chi-square test. 
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Table 4 
Causes of diagnostic delay in breast cancer diagnosis following recall at screening mammography.  
Cause of diagnostic delay, N (%) Year of screening Total  
1997− 2001 2002− 2006 2007− 2011 2012− 2016  
Incorrect radiological classification 20 (42.6) 21 (39.6) 40 (58.0) 51 (72.9) 132 (55.2) 
False negative percutaneous biopsy 10 (21.3) 16 (30.2) 15 (21.7) 11 (15.7) 52 (21.8) 
Probably benign lesion at radiology (BI-RADS 3) followed by radiological surveillance 10 (21.3) 12 (22.6) 12 (17.4) 4 (5.7) 38 (15.9) 
False negative surgical (excision) biopsy 4 (8.5) 1 (1.9) 0 (0) 2 (2.9) 7 (2.9)  
Other:      
Surgical oncologist does not follow radiologist’s advice of (repeated) lesion biopsy 1 (2.1) 1 (1.9) 1 (1.4) 0 (0) 3 (1.3) 
Surgical oncologist does not follow pathologist’s advice of lesion excision 1 (2.1) 1 (1.9) 0 (0) 0 (0) 2 (0.8) 
Surveillance of a radiologically suspicious lesion which is inaccessible to percutaneous biopsy 0 (0) 0 (0) 1 (1.4) 1 (1.4) 2 (0.8) 
Patient refuses biopsy 1 (2.1) 1 (1.9) 0 (0) 1 (1.4) 3 (1.3) 
Total 47 53 69 70 239 
BI-RADS = Breast Imaging Reporting and Data System. 
Fig. 2. Patient example of a 12-month delay 
due to erroneous BI-RADS classification by the 
clinical radiologist. Two-view screening mam-
mograms (A and C, cranio-caudal (CC) view, 
and B and D, medio-lateral oblique (MLO) 
view) of the right breast at recall in 2013. Im-
ages A and B show a lesion in the retroareolar 
region of the breast (white arrows), classified as 
BI-RADS 4 by the screening radiologists. Digital 
breast tomosynthesis and ultrasound were per-
formed, and the lesion was classified as BI- 
RADS 2 (benign lesion). No biopsy was per-
formed. Twelve months later the patient re-
ported to the surgical department with a 
growing lump in the right breast. Images C and 
D in 2014 show increased density of the retro-
areolar lesion in the right breast (white arrows), 
with possible satellite lesions (white arrow-
heads). Targeted ultrasound showed an irreg-
ular, hypoechogenic lesion with satellite 
lesions, which was classified as BI-RADS 5. Ul-
trasound guided true-cut biopsy was performed 
which revealed an invasive ductal carcinoma 
with axillary metastases (TNM: T3N2M0). The 
patient was treated with neo-adjuvant chemo-
therapy, mastectomy, radiotherapy, and hor-
monal therapy.   
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Fig. 3. Patient example of a 24-month delay due to 
erroneous BI-RADS classification by the clinical radiolo-
gist. Two-view screening mammograms (A and C, cranio- 
caudal (CC) view, and B and D, medio-lateral oblique 
(MLO) view) of the right breast at recall in 2015 show a 
lesion in the upper lateral quadrant of the right breast. 
Images A and B show the lesion in 2015 (white arrows), 
classified as BI-RADS 4 by the screening radiologists. 
Digital breast tomosynthesis and ultrasound were per-
formed, and the lesion was classified as BI-RADS 2 
(benign lesion). No biopsy was performed. At repeated 
recall in 2017 for the same lesion (again characterized as 
BI-RADS 4 by the screening radiologists), increased den-
sity of the lesion was seen, with an increase in size (im-
ages C and D). Targeted ultrasound showed a spiculated, 
irregular and hypoechogenic lesion, which was classified 
as BI-RADS 5. Ultrasound guided true-cut biopsy was 
performed which revealed an invasive ductal carcinoma. 
There were no axillary metastases (TNM: T1bN0). The 
patient was treated with breast conserving surgery and 
adjuvant radiotherapy.   
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women who underwent follow-up imaging for a BI-RADS 3 abnormality 
experienced a diagnostic delay as a result of non-adherence to the rec-
ommended follow-up examinations. 
4. Discussion 
In the current study we found that the proportion of recalled women 
with a delay of at least four months in their confirmation of breast cancer 
more than halved during two decades of screening mammography. This 
reduction was mainly due to the sharp decline in the number of women 
with a delay of 4− 24 months in their breast cancer diagnosis. At the 
same time, the number of women who experienced a delay of at least 24 
months in their breast cancer diagnosis, per 1000 screen-detected can-
cers, has remained stable over the years. Tumours that were diagnosed 
after a delay of at least 24 months were more often invasive and less 
frequently Her2/Neu positive compared to breast cancers that were 
confirmed after a delay of 4− 24 months, but other tumour histology 
characteristics, tumour size and nodal status were comparable for both 
groups. Frequent causes of delay included incorrect radiological classi-
fication at recall and false negative percutaneous biopsy. 
Several studies have shown that longer diagnostic and therapeutic 
intervals may have a detrimental effect on breast cancer survival. 
Therefore, a timely diagnosis of breast cancer not only requires the 
recognition of suspicious mammographic findings at screening, but it 
also necessitates a prompt confirmation of the malignancy after recall. 
Over the years, we observed a significantly reduced probability of a 
delayed breast cancer confirmation after recall. The last decade has seen 
substantial changes in the diagnostic management of (a)symptomatic 
breast disease, with the introduction of multi-disciplinary meetings and 
new imaging modalities (e.g., digital breast tomosynthesis), an intensi-
fied use of advanced imaging modalities (breast MRI), a further 
replacement of fine needle biopsy by (vacuum assisted) large core bi-
opsy, and an increased sub-specialization of physicians in breast care [6, 
12,13]. These developments have likely resulted in the decline of 
women facing a delayed breast cancer confirmation. However, this 
improvement was mainly present for diagnostic delays of less than 24 
months but not for longer delays. All Dutch screening radiologists are 
trained and certified by the Dutch Expert Centre for Screening (LRCB). 
This centre increasingly emphasizes a timely confirmation of the benign 
or malignant nature of a recalled mammographic abnormality [14,15]. 
The LRCB therefore discourages abnormalities to be classified as prob-
ably benign at workup, if possible, as these lesions require follow-up for 
6–24 months. Although this policy shortens the period of uncertainty 
among recalled women and helps to reduce short delays after recall, it 
may at the same time result in longer diagnostic delays, i.e. when 
radiological re-evaluation of a probably benign breast lesion at 
follow-up would have resulted in additional biopsy rather than a second 
recall for the same mammographic abnormality at a later screening 
round. The shift from shorter to longer diagnostic delays is related to the 
finding that the most frequent cause of a diagnostic delay in this study 
was an incorrect radiological classification at workup, with a propor-
tional increase of these delays over the years. At the same time, the 
probability to experience a delayed breast cancer confirmation as a 
result of radiological surveillance of a probably benign lesion decreased, 
as a decrease in the amount of BI-RADS 3 classifications after radio-
logical recall was seen (from 21.3 % in 1997− 2001 to 5.7 % in 
2012− 2016, P = 0.01). Diagnostic improvements at screening 
mammography result in an increased lesion detection, reflected by 
increased recall rates and cancer detection as shown previously [16–19]. 
Subtle lesions may have a larger potential to receive an incorrect workup 
after recall and may also lead to equivocal findings necessitating addi-
tional follow-up. It is subject of debate whether a delayed diagnosis of 
small lesions significantly influences prognosis and further studies are 
needed to address this topic [4,13]. We found that the size of the cancers 
with a diagnostic delay was comparable to those of screen-detected 
cancers, with a similar grading and less lymph node involvement. 
Therefore, the prognosis of both groups will most likely be comparable, 
whereas the diagnostic delay will have a certain negative impact on 
survival due to increase in tumour size and the development of nodal 
involvement during the diagnostic delay [13]. Several studies have 
shown that interval cancers have a significantly worse prognosis than 
screen-detected cancers [20,21]. However, our paper focuses on cancers 
diagnosed in recalled women and we did not evaluate interval cancers. 
Nevertheless, it will be very interesting and clinically valuable to 
determine the contribution of delayed cancer diagnoses in recalled 
women among all potentially preventable delayed cancer diagnoses. 
This requires the determination of the proportion and tumour charac-
teristics of “missed” cancers among all interval cancers, as well as the 
determination of these parameters for screen-detected cancers that were 
missed at the previous screening round. This issue is definitely a topic for 
further research. 
The breast cancers in the two groups of diagnostic delays showed 
comparable tumour characteristics except of fewer DCIS and more 
Her2/Neu negative invasive cancers among women with a longer delay. 
DCIS is usually detected through the presence of calcifications at 
mammography. The availability of stereotactic core needle biopsy as an 
alternative to surgical biopsy has gradually resulted in a routine biopsy 
of BI-RADS 3 calcifications rather than follow-up, which may explain the 
low proportion of DCIS among women experiencing a long delay in their 
breast cancer confirmation. To improve the communication between 
screening radiologists and clinicians, the BI-RADS classification for 
mammographic abnormalities was implemented in the Dutch screening 
mammography programme in 2009, along with the replacement of 
screen-film by digital screening mammography [15,22]. The BI-RADS 
classification system increases inter-observer agreement between 
breast radiologists and helps to guide the diagnostic pathways at recall. 
A further reduction in the number of women with a delayed breast 
cancer confirmation may be obtained by restricting the workup to 
dedicated breast radiologists in accredited hospitals. The Dutch 
screening programme differs from those in several other European 
countries and the USA as screening and recall are not integrated. Hos-
pitals handling recalled women are separated from the screening units 
and quality control of the workup is not mandatory [15,23]. The Dutch 
Fig. 4. Trends in causes of delayed breast cancer diagnosis per 1000 screen 
detected cancers. 
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screening programme, however, is subject to quality assurance, consis-
tent with recommendations of the European Society of Breast Imaging 
(EUSOBI) and International Agency for Research on Cancer (IARC) 
[23–26]. The introduction of quality assurance and assessment sessions 
may prove beneficial for hospitals handling recall, reducing the number 
of recalled women facing a delayed cancer diagnosis. 
Our study has several strengths and limitations. To our knowledge, 
this is the first study focusing on time trends in delayed breast cancer 
confirmation after recall for a screen detected mammographic abnor-
mality. A large series of consecutive screening mammograms with 
almost complete follow-up was analysed during two decades of 
screening mammography. On the other hand, the relatively short follow- 
up period of at least 3.5 years may not have enabled us to identify all 
cases with a longer delay in the most recently screened cohort. Also, 
screening mammography programmes are continuously subject to 
changes and the design of these programmes differs among countries. 
Assessment after recall may be performed in hospitals that are not linked 
to the screening programme, like in the Netherlands, or may be 
embedded in the screening procedure itself. The missing data of the 
Her2/Neu-receptor status in patients with a 4− 24 months of delay may 
have hampered statistical analysis. Unfortunately, we do not have data 
available on the amount of clinical mammograms read by screening 
radiologists and non-screening radiologists. It will be interesting to 
investigate whether the quality of the breast imaging assessments after 
recall differs between screening and non-screening radiologists but we 
currently lack the data to analyse this issue. 
We conclude that the proportion of recalled women with a delay in 
their confirmation of breast cancer has significantly decreased during 
two decades of screening mammography, but these delays are now 
characterized by longer delay intervals. Quality assurance should not 
only cover the screening mammography programmes, but it should also 
focus on the hospitals handling the workup of recalled women, in order 
to prevent a worse breast cancer survival due to a delayed breast cancer 
confirmation. Currently, none of the Dutch hospitals are involved in a 
mandatory or non-mandatory quality assurance programme concerning 
the handling of women recalled at screening mammography, although 
the hospitals can receive a yearly distinction on breast cancer care in 
general. With the results of our study we hope to be able to start a dis-
cussion about the necessity to start a quality assurance programme for 
hospitals involved in the evaluation of women recalled at screening 
mammography. 
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